Supernus Pharmaceuticals | SUPN - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Abbott USD 4.27B 669M 2026-09
ANI Pharmaceuticals USD 94.86M 3.2M 2026-09
Aurora Cannabis CAD 40.89M 515K 2026-06
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Canopy Growth CAD 33.99M 2.83M 2026-06
Cara Therapeutics USD 2.09M 96K 2026-03
Corcept Therapeutics USD 142.04M 14.86M 2026-09
Eisai JPY 120.4B 5.58B 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Novo Nordisk DKK 16.31B 3.09B 2026-06
Pacira USD 950.8M 858.99M 2026-09
Perrigo USD 271.7M 3.01B 2026-09
Pfizer USD 3.28B 132M 2026-09
Supernus Pharmaceuticals USD 133.64M 15.41M 2026-06
United Therapeutics USD 184.1M 22.6M 2026-09
Xeris Pharmaceuticals USD 61.04M 7.89M 2026-06